Suprema Inc (236200) Fair Value & Analysis
Industrials · KR · Market cap 311B KRW
Fair value as of: Jun 25, 2026
Analysis
Suprema Inc (236200) currently trades at 41,400 KRW, while our model-based Fair Value estimate is 106,517 KRW — implying the stock looks roughly 157.3% undervalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Suprema Inc. develops and manufactures biometric and security products in South Korea and internationally. The company offers biometric access control systems, time and attendance solutions, fingerprint live scanners, mobile authentication solutions, and embedded fingerprint modules. It also provides access control, mobile access, and time and attendance solutions; BioSign, a mobile authentication solution; and integrated solutions, including BioStar 2, a Web-based security platform that enables to integrate with third-party systems. In addition, the company offers biometric readers, rf/ mobile readers, intelligent controller, open platform, peripherals, and OEM fingerprint modules. It serves construction, data center, healthcare, commercial, infrastructure, and manufacturing industries. Suprema Inc. was founded in 2000 and is headquartered in Seongnam-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Suprema Inc (236200) undervalued?
What is the fair value of 236200?
What is the quality score of 236200?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.